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Gefitinib (‘Iressa’, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, has recently been approved in several
countries for use in advanced or metastatic non-small-cell lung cancer (NSCLC). In contrast to chemotherapies, which are generally
used at or near their maximum-tolerated dose (MTD), gefitinib is used at an optimal biological dose (250mgday
 1), which is
substantially below its MTD, minimising the risk of adverse events without compromising efficacy. Tolerability data from the
compassionate use of gefitinib in the ‘Iressa’ Expanded Access Programme support the favourable safety profile of the agent reported
in Phase I and II trials. In both settings, the majority of adverse drug reactions were mild/moderate and consisted mainly of grade 1/2
diarrhoea and skin rash. Although skin rash has been suggested to predict response to gefitinib, available data do not support this
hypothesis. Overall, these tolerability data demonstrate that gefitinib has a relatively benign side-effect profile and is a well-tolerated
treatment option for patients with previously treated NCSLC, who currently have few alternatives.
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In advanced non-small-cell lung cancer (NSCLC) platinum
doublets are regarded standard for palliative therapy for patients
of performance status (PS) 0–1, but their palliative use is hindered
by the toxicity elicited by these combinations. Cisplatin induces
nausea and vomiting in a majority of patients and is also
associated with nephrotoxicity, neurotoxicity, ototoxicity and
anaemia (BC Cancer Agency, 2003; British National Formulary,
2003). In a significant number of cases these toxic effects result in
dose reduction or withdrawal of cisplatin and transfer of the
patient to an alternative treatment. Less fit patients (PS X2) with
NSCLC are advised to avoid platinum-based treatments (Schiller
et al, 2002) and frequently receive single-agent chemotherapies
first line. Gemcitabine, vinorelbine and the taxanes are being used
as single agents for this indication and, although much better
tolerated than in combination with platinum agents, their use may
also be complicated by side effects.
The approved second-line chemotherapy option for patients of
PS 0–1 who either cannot tolerate or who fail first-line platinum-
based treatment is docetaxel. The administration of docetaxel
is associated with prominent side effects such as neutropenia,
alopecia, leucocytopenia and nail changes (BC Cancer Agency,
2003; British National Formulary, 2003). Patients receiving
chemotherapies need to be closely monitored to avoid complica-
tions and discontinuation of treatment.
The toxicity issues that surround the use of standard
chemotherapy highlight the clinical need for novel anticancer
agents that have a mode of action that is different from
the indiscriminate action of cytotoxic chemotherapies. It is
anticipated that such agents will combine targeted antitumour
activity with improved tolerability over cytotoxic agents. Gefitinib
(‘Iressa’, ZD1839), an epidermal growth factor receptor tyrosine
kinase inhibitor (EGFR-TKI), is an example of a targeted agent that
has demonstrated favourable tolerability and durable antitumour
activity in clinical trials in patients with advanced NSCLC
(Fukuoka et al, 2003; Kris et al, 2003). The assessment of the
gefitinib safety data reported via the ‘Iressa’ Clinical Experience
(ICE) meeting, held in June 2003 in Madrid, Spain, provided
valuable insight into the tolerability of the agent in everyday
clinical practice. This article summarises the safety and tolerability
findings from this experience and assesses how they compare
with the safety and tolerability conclusions from the pivotal
Phase II studies (Fukuoka et al, 2003; Kris et al, 2003). We also
explore the biological basis of the good tolerability of gefitinib
and discuss the impact of the agent’s side-effect profile on its
risk:benefit ratio.
TOLERABILITY OBSERVED IN IDEAL TRIALS
The tolerability of gefitinib 250 or 500mgday
 1 was assessed in
two randomised, double-blind trials in 425 pretreated patients with
advanced or metastatic NSCLC. The ‘Iressa’ Dose Evaluation in
Advanced Lung cancer (IDEAL) 1 trial enrolled 209 patients from
centres in Europe, Australia, South Africa and Japan, all of whom
had received p2 prior regimens, including one that was platinum
based (Fukuoka et al, 2003). IDEAL 2 recruited 216 patients in the
USA, who had previously received X2 chemotherapy regimens,
including a platinum compound and docetaxel, used either
together or as separate regimens (Kris et al, 2003). The safety
profile of gefitinib demonstrated in these trials was consistent with
that reported in the Phase I trials, and no unexpected adverse drug
reactions (ADRs) were observed. The most common ADRs were
mild (grade 1 or 2) and consisted mainly of diarrhoea and skin *Correspondence: Dr Nico van Zandwijk; E-mail: n.v.zandwijk@nki.nl
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treatment. Although the profile of grade 1/2 ADRs was similar
for both doses, grade 1/2 ADRs were more frequently reported
with gefitinib 500mgday
 1. For example in IDEAL 2, grade 1/2
diarrhoea was reported in 56% of patients receiving gefitinib
250mgday
 1 and 69% of those receiving 500mgday
 1. Grade 3/4
ADRs were also dose related. In both trials, a higher incidence of
grade 3/4 ADRs was reported in patients receiving gefitinib
500mgday
 1 than in those receiving the lower dose (23.6 vs 7.8%,
respectively). Most of the ADRs were manageable and noncumu-
lative. In both trials, few patients discontinued gefitinib due to
ADRs (1.5% for 250mgday
 1 and 6.8% for 500mgday
 1). These
data show that, although both doses of gefitinib were generally well
tolerated, the 250mgday
 1 dose was better tolerated overall. As
efficacy data from the IDEAL trials showed that both doses had
similar antitumour activity, these data support 250mgday
 1 as the
recommended dose for advanced NSCLC because it provides
effective clinical benefit and retains favourable tolerability.
TOLERABILITY OF GEFITINIB IN EVERYDAY
CLINICAL PRACTICE
Centres participating in the ‘Iressa’ Expanded Access Programme
(EAP) have administered gefitinib 250mgday
 1 to patients with
advanced NSCLC on a compassionate basis. The Netherlands
Cancer Institute case series is one of the largest groups of patients
(n¼100) from a single institution for which EAP experience is
available (Haringhuizen, ICE abs; Haringhuizen et al, 2003). (See
appendix for ICE abstracts). Results from this case series were
discussed in detail at the ICE meeting. In this case series, 450% of
patients presented with adenocarcinoma and stage IV disease
(Table 1). A substantial proportion of patients (approximately
33%) were unfit for chemotherapy and had PS X2. The majority of
patients (62%) had received one prior chemotherapy regimen and,
of these, 94.1% had received platinum-based treatment. Consistent
with the tolerability profile of gefitinib in clinical trials, the
majority of adverse events experienced by these patients in this
EAP study were mild (grade 1/2) and the most common grade 1/2
adverse effects were skin rash, diarrhoea and desquamation/
itching (34.0, 21.8 and 21.8% of patients, respectively) (Harin-
ghuizen, ICE abs). Grade 3/4 adverse events were rare and linked
to skin and gastrointestinal adverse events (Tables 2 and 3).
Gefitinib was well tolerated by most patients and o6% of patients
withdrew/discontinued treatment due to adverse events.
A further six case series, each consisting of 445 patients,
were also submitted to the ICE meeting (Gridelli [a], ICE abs;
Gridelli [b], ICE abs; Bianco, ICE abs; Cortes-Funes, ICE abs;
Chioni, ICE abs; de Braud, ICE abs). Their safety findings are
consistent with tolerability results from The Netherlands Cancer
Institute case series (Haringhuizen, ICE abs) and are also
summarised in Table 3.
Overall, data from all these case series (Haringhuizen, ICE abs;
Gridelli [a], ICE abs; Gridelli [b], ICE abs; Bianco, ICE abs; Cortes-
Funes, ICE abs; Chioni, ICE abs; de Braud, ICE abs) (total n ¼
521) show that gefitinib is well tolerated by pretreated patients
with NSCLC in everyday clinical practice. Most of the common
adverse events were mild/moderate and the majority were grade
1/2 diarrhoea and skin rash (Figures 1 and 2). Grade 3/4 adverse
events were reported rarely (Table 3). Similar findings concerning
the good tolerability of gefitinib in everyday clinical practice have
also been reported by other large EAP case series in both adult
(Lo ´pez Martin et al, 2003; Park et al, 2003) and elderly patients
(Soto Parra et al, 2003).
Analysis of the safety data from gefitinib-treated patients
has shown that unexpected or unusual adverse events with
gefitinib are rare. One such rare event that has been recently
featured in the media is interstitial lung disease (ILD), which was
stimulated by the publication of a Japanese report of four patients
who experienced interstitial pneumonia while receiving gefitinib
(Inoue et al, 2003). ILD is not an uncommon event in patients who
receive therapy for NSCLC and it may occur as a sign of
progression of the disease itself (metastatic/lymphomytic spread)
or as a consequence of its treatment. Standard lung cancer
treatments, such as chemotherapy and radiotherapy, are able to
elicit ILD, with incidences of 10% and higher reported (Chen
et al, 2000; Thomas et al, 2000; Rebattu et al, 2001; Willner
et al, 2001; Bhatia et al, 2002). ILD was not reported with gefitinib
250mgday
 1 in the IDEAL trials and has been reported rarely
during its wider use in clinical practice. Four cases of ILD
were reported at the ICE meeting (Haringhuizen, ICE abs;
Overbeck and Griesinger, ICE abs; Cortes-Funes, ICE abs; Gervais,
ICE abs). Analysis in over 92000 patients worldwide, who
have received gefitinib to date (September 2003), has shown
that the incidence of ILD-type events was less than 1%
(Forsythe and Faulkner, 2003). The frequency of ILD-type events
in Japanese patients (1.9%) appears to be higher than in the rest of
the world (0.3%); the reason for this is unknown, although it may
be related to population or environmental differences or
differences in clinical practice. Of interest, this observed ethnic
difference in reporting rates does not extend to other South East
Asian countries (eg China, Hong Kong, Korea, Malaysia,
Philippines, Singapore, Taiwan and Thailand), where the fre-
quency of reporting ILD is comparable to that in the rest of the
world (0.3%). Further investigations to clarify the reasons for such
an ethnic stratification in ILD incidence following treatment are
underway.
Overall, these safety data from the EAP are consistent with the
findings from the IDEAL trials, and confirm that gefitinib is a well-
tolerated anticancer agent. Most of its side effects are mild and
unusual or unexpected side effects are rare.
Table 1 The Netherlands Cancer Institute EAP experience – patient
demography (Haringhuizen et al, 2003)
Patients, n, evaluable/nonevaluable 92/8
Male/female, n 48/44
WHO/ECOG performance status
a 0/1/2/3/4 9/37/22/7/1
Histology (%)
Adenocarcinoma 51
Squamous-cell carcinoma 20
Large-cell carcinoma 15
Bronchioalveolar carcinoma 6
Stage III/IV 13/79
Previous chemotherapy, n
Chemonaive 7
First line 57
Second line 19
Third line 7
Fourth line 2
WHO, World Health Organization; ECOG, Eastern Cooperative Oncology Group.
aNot recorded in 16 patients.
Table 2 The Netherlands Cancer Institute EAP experience – adverse
events (n¼92) (Haringhuizen, ICE abs)
Grade 1
(%)
Grade 2
(%)
Grade 3
(%)
Grade 4
(%)
Diarrhoea 19.6 2.2 1.1 1.1
Skin rash 19.6 14.4 1.1 —
Desquamation/itching 20.7 1.1 1.1 —
Nausea/vomiting 14.1 4.4 — —
Anorexia 13.0 10.9 — —
Liver-enzyme elevation 3.3 2.2 — —
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Standard chemotherapeutic agents are cytotoxic drugs that kill
dividing cells so their antitumour activity and toxic effects are
generally seen within the same dose range. The dose of chemother-
apy drugs selected for clinical use is usually the maximum-tolerated
dose (MTD) (Figure 3A). In contrast, as gefitinib is used at an
optimal biological dose (OBD), which is substantially below its
MTD, the risk of adverse events is minimised without compromi-
sing efficacy (Figure 3B) (Rowinsky, 2000). The pharmacodynamic
differences between biologically targeted agents and standard
chemotherapeutics may explain why gefitinib has a more favourable
side-effect profile than some traditional chemotherapies.
Clinical evidence from Phase I and II trials has demonstrated
that gefitinib has a wide therapeutic margin that enables it to be
used at a dose that provides the optimal balance of efficacy and
Table 3 Safety and tolerability observations from eight case series 445 patients
a with advanced NSCLC who received gefitinib compassionately through
the gefitinib EAP
Author
Patients treated
(evaluable), n
Median age
and/or
range (years)
Histology/disease
stage
Prior treatment
experience
Overall
assessment of gefitinib tolerability by
author
Haringhuizen, ICE
abs
92 (92) 33–76 62% Adenocarcinoma 92% Xfirst-line
chemotherapy
Good tolerability. Most side effects were mild. Most
frequent side effects were grade 1/2 skin rash,
diarrhoea and desquamation/itching (34.0, 21.8 and
21.8% of patients, respectively). ILD without
symptoms observed in one (1%) patient, which
resolved during treatment
14% Stage III
86% Stage IV
Gridelli [a], ICE abs 59 (57) 46% Adenocarcinoma 97% Xfirst-line
treatment
Good tolerability in both elderly and unfit patients.
Elderly group: the most frequent adverse events
were grade 1/2 skin changes in five (28%) patients
and grade 1 diarrhoea in three (17%) patients. PS
X2 group: the most frequent adverse events were
grade 1 diarrhoea in two (5%) patients and grade 2
hypertransaminasaemia in one (3%) patient
18 (18) (Elderly) 73.5 46% Squamous-cell
41 (39) (PS X2) 60 2% Bronchioalveolar
7% Other
12% Stage IIIb
88% Stage IV
Gridelli [b], ICE abs 83 (71) 33–80 47% Adenocarcinoma 98% Xfirst-line
treatment
Good tolerability. The most frequent adverse
events were grade 1/2 skin changes and grade 1
diarrhoea (11 and 10% of patients, respectively).
Other reported adverse events: grade 2
hypertransaminasaemia in one (1%) patient and
grade 1 epistaxis in one (1%) patient
42% Squamous-cell
2% Bronchioalveolar
8% Other
13% Stage IIIb
87% Stage IV
Bianco, ICE abs 49 (49) 59 (29–80) 49% Adenocarcinoma 100% Xsecond-
line chemotherapy
Tolerability was excellent, two (4%) patients
experienced mild, drug-related skin rash PS p2 47% Squamous-cell
2% Bronchioalveolar
2% Large-cell
16% Stage IIIb
84% Stage IV
Cortes-Funes, ICE
abs
113 (113) 61 (36–83) 41% Adenocarcinoma 79% Xsecond-line
chemotherapy
Well tolerated. Most side effects were mild/
moderate. The most frequent adverse events were
grade 1/2 skin toxicity 42.5% patients (3.5% grade
3/4), diarrhoea 21.2% patients (0.9% grade 3/4) and
20.4% asthenia (5.3% grade 3/4). Other adverse
events included nausea and vomiting (grade 1/2
10.6%; grade 3/4 0.9%), anorexia (9.7%; 3.5%),
neurological toxicity (9.7%; 1.8%) and pulmonary
toxicity (0.9%; 0.9%)
40% Squamous-cell
15% large-cell
4% Other
30% Stage I-IIa
70% Stage IIIb-IV
Chioni, ICE abs 74 (72) 65 (43–81) 24% Adenocarcinoma 53% second-line
chemotherapy
Well tolerated. Most side effects were mild: grade 1
diarrhoea (5.4%) and cutaneous toxicity (8%). Two
patients had grade 3 diarrhoea (3%) and one
patient had grade 3 diarrhoea plus cutaneous
toxicity (1%)
36% Squamous-cell
9% Bronchioalveolar
14% Undifferentiated
large-cell
16% Other
Disease stage not
reported
de Braud , ICE abs 79 (67) 56 (31–77) 65% Adenocarcinoma Median number of
chemotherapy
regimens¼2
range (1–6)
Well tolerated. Most side effects were mild/
moderate grade 1/2 skin reactions (30%), diarrhoea
(9%) and nausea (4%). Grade 3/4 skin reactions
occurred in 2% of patients
18% Squamous-cell
4% Bronchioalveolar
5% Other
Locally advanced or
metastatic disease
aCase series were discussed at the ‘Iressa’ Clinical Experience (ICE) meeting and provided information on safety and tolerability. ILD¼interstitial lung disease; EHP¼Expanded
Access Programme; NSCLC¼non-small-cell lung cancer.
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from Phase I clinical trials, where the data suggested that gefitinib
had biological and clinical activity over the complete dose range
studied (150–1000mgday
 1) (Baselga et al, 2002; Herbst et al,
2002; Ranson et al, 2002; Nakagawa et al, 2003). On the basis of
these data, two dose levels (250 and 500mgday
 1) were selected
for Phase II/III studies, which were both significantly below the
X700mgday
 1 MTD of gefitinib identified in Phase I clinical trials
(Ranson et al, 2002). Gefitinib 250mgday
 1 was chosen because it
was above the lowest dose shown to effect antitumour activity and
gefitinib 500mgday
 1 selected as it was the highest dose that was
well tolerated by most patients during long-term use. Gefitinib was
evaluated at these dose levels in the IDEAL trials and the data
showed that both gefitinib 250 and 500mgday
 1 provided similar
efficacy, but that the higher dose was associated with a higher
frequency and severity of ADRs (Fukuoka et al, 2003; Kris et al,
2003) (Figure 4).
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Figure 1 Incidence of diarrhoea in six case series with X45 patients
from the ICE meeting that reported diarrhoea as a commonly occurring
adverse event (Haringhuizen, ICE abs; Gridelli [a], ICE abs; Gridelli [b], ICE
abs; Cortes-Funes, ICE abs; Chioni, ICE abs; de Braud, ICE abs)
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Figure 2 Incidence of skin rash in seven case series with X45 patients
from the ICE meeting that reported skin rash as a commonly occurring
adverse event (Haringhuizen, ICE abs; Gridelli [a], ICE abs; Gridelli [b],
ICE abs; Bianco, ICE abs; Cortes-Funes, ICE abs; Chioni, ICE abs; de Braud,
ICE abs)
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Figure 3 Idealised curves reflecting molecular target effects, antitumour
effects and toxicity as functions for (A) a typical cytotoxic agent
whose toxicity occurs at roughly the same dose as target effects and
(B) a hypothetical target-based antiproliferative agent whose target effects
occur at lower doses than toxic effects. Adapted with permission from:
Rowinsky EK (2000)
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Figure 4 Relationship between gefitinib dose, objective response and
rash. From: Herbst R (2003), with permission from Elsevier
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As detailed above, mild skin rash is one of the most common ADRs
associated with gefitinib. Recent reports have suggested that skin
rash may predict clinical response to EGFR inhibitors. These
assumptions are based on the observations that most patients with
a response, stable disease or long-term survival have a skin rash,
there is a higher incidence of rash among responders than
nonresponders and that survival end points are longer in patients
with rash. These observations have been reported with the EGFR
inhibitors gefitinib (Cohen et al, 2003; Janne et al, 2003), erlotinib
(Perez-Soler et al, 2001) and cetuximab (Kies et al, 2002).
However, as patients with an objective response generally receive
treatment for longer than those with disease progression, it might
be expected that there would be a higher incidence of rash in these
patients, suggesting that simultaneous occurrence of rash and
response may be coincidental. It is conceivable, however, that
early-onset rash (one which develops within 14–28 days) may be
more relevant to response than rash that develops later in
treatment. To investigate this further, a retrospective analysis
examined the onset of early rash in patients with NSCLC who
received gefitinib in IDEAL 2 and survived X28 days of treatment.
Multivariate analysis found no statistically significant association
between early-onset skin toxicity (skin rash, pruritus, acne, dry
skin) and objective response rate with either gefitinib 250 or
500mgday
 1. By day 14, eight of the 12 patients (67%) who
ultimately responded to gefitinib 250mgday
 1 had not developed
any skin toxicity and by day 28, three of the 12 (25%) responders
had not yet developed skin toxicity. Retrospective assessment of
incidence of skin rash in both IDEAL trials has shown that nine of
the 31 responders (29%) to gefitinib 250mgday
 1 did not
experience skin rash at any time during treatment. Data from
the gefitinib clinical trial programme have also shown that the
incidence of skin rash, but not response, increases with increasing
dose. In Phase I trials, in which gefitinib was tested over the dose
range 150–1000mgday
 1, the incidence of rash correlated with
escalating dose: from approximately 30% at 150mgday
 1 to
approximately 80% at 1000mgday
 1 (Baselga et al, 2002; Herbst
et al, 2002; Ranson et al, 2002; Nakagawa et al, 2003). Correlation
between dose and skin rash was also evident in the Phase II IDEAL
trials, where gefitinib 500mgday
 1 was associated with a higher
incidence of rash but similar objective response rates and survival
as the 250mgday
 1 dose.
These clinical data are supported by results from a study that
analysed the pharmacodynamic effects of gefitinib in paired skin
biopsies from patients who were receiving gefitinib 150–
1000mgday
 1 in Phase I trials (Albanell et al, 2002). The study
found that gefitinib inhibited skin EGFR activation at all doses
X150mgday
 1 and that there was no significant correlation
between pharmacodynamic effects and skin toxicity.
Together, these clinical and experimental data do not support
the hypothesis that skin toxicity predicts response to gefitinib.
DISCUSSION
It is encouraging that the favourable safety profile of gefitinib
demonstrated in Phase I and II trials is consistent with that
observed in everyday settings. Data from clinical trials and the
EAP indicate that gefitinib is well tolerated by patients with
advanced or metastatic NSCLC. The majority of ADRs associated
with gefitinib are mild in nature and those most commonly
reported are grade 1/2 diarrhoea and skin reactions. Although
skin rash has been hypothesised to be a potential prognostic
factor for response to EGFR inhibitors, the lack of correlation
between skin rash and clinical benefit over a wide range of gefitinib
doses (150–1000mgday
 1) in clinical trials demonstrates that
it should not be used to direct treatment with gefitinib. The
analysis of trial data has shown that not all responders to gefitinib
experience skin rash. Hence, it would seem inappropriate to
use skin rash as a surrogate marker of response to gefitinib
as it would deny patients who do not experience skin rash the
potential to obtain benefit from treatment. Until more predictive
molecular markers are identified, symptom improvement should
be used as a meaningful prognostic indicator of the clinical benefit
of gefitinib.
The relatively benign side-effect profile of gefitinib is very
different from the safety profile of standard chemotherapy
agents, with which patients frequently experience serious ADRs
such as haematological toxicity, neurotoxicity, and nausea
and vomiting. Often the severity of these ADRs requires medical
intervention and in some cases patients will need to be hospitalised
for management of toxicity caused by chemotherapy. In contrast,
use of gefitinib in clinical trials and in everyday clinical practice
shows that grade 3/4 ADRs and unexpected/unusual ADRs
are rare. In addition, the findings show that the agent is not
associated with cytotoxic ADRs and any nausea and vomiting
experienced by patients during gefitinib treatment is generally
mild to moderate.
It is suggested that pharmacodynamic differences between
gefitinib and cytotoxic chemotherapies may account for gefitinib’s
favourable tolerability. Traditional chemotherapies are used at
their MTD to exert their maximum efficacy but at the cost of
a high level of toxicity and poor tolerability. In contrast,
well-designed randomised dose-finding trials in NSCLC
have demonstrated that gefitinib doses higher than 250mgday
 1
do not give a better response and cause increased toxicity.
Hence, gefitinib is recommended to be used at an OBD
(250mgday
 1) that provides clinical benefit while retaining
favourable tolerability.
The contrasting safety profiles of gefitinib and chemotherapy
highlight the important new approach that gefitinib brings to
NSCLC. In addition to providing clinical benefit to a subset of
patients with advanced or metastatic disease, the favourable safety
profile of gefitinib avoids toxic reactions commonly seen with
standard chemotherapy.
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